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Background. For the treatment of visceral leishmaniasis in Bangladesh, single dose liposomal amphotericin B (ambisome) is
supposed to be the safest and most effective treatment. Specific needs for application and storage raise questions about feasibility of
its implementation and acceptance by patients and health staff.Methods.The study was carried out in the most endemic district of
Bangladesh. Study population includes patients treated with ambisome or miltefosine, hospital staff, and a director of the national
visceral leishmaniasis program. Study methods include direct observation (subdistrict hospitals), open interviews (heath staff and
programpersonnel), structured questionnaires, and focus group discussions (patients).Results.Politicalcommitment for ambisome
is strong; the general hospital infrastructure favours implementation but further strengthening is required, particularly for drug
storage below 25∘C (refrigerators), back-up energy (fuel for generators), and supplies for ambisome administration (like 5%dextrose
solution). Ambisome created high satisfaction in patients and hospital staff, less adverse events, and less income loss for patients
compared tomiltefosine.Conclusions.High political commitment, general capacities of subdistrict hospitals, and high acceptability
favour the implementation of ambisome treatment in Bangladesh. However, strengthening of the infrastructure and uninterrupted
supplies of essential accessories is mandatory before introducing sLAB in Bangladesh.
1. Background
Visceral leishmaniasis (VL), also called Kala-azar (KA), is a
vector borne neglected disease ranked by the WHO as the
infectious disease with the ninth highest burden worldwide
[1]. More than 70 per cent of the cases worldwide occur
in India, Bangladesh, and Nepal [2]. The annual incidence
for Bangladesh has recently been estimated to be between
12,400 and 24,900 cases [2]. Out of the 64 districts and 493
subdistricts of Bangladesh, 45 districts and 105 subdistricts
are affected [3].
L. donovani causing VL in the region has no other reser-
voir than humans and no other vector other than Phlebot-
omus argentipes. There are new rapid diagnostic tests [4]
and different treatment options so that the elimination of the
disease was envisaged. In 2005 a Memorandum of Under-
standing was signed by Bangladesh, India, and Nepal to eli-
minate VL from the Indian subcontinent aiming for less than
one case per 10,000 people in the endemic districts by 2015
[5].
One important element in the elimination strategy is early
diagnosis and complete treatment. Within the last decade
new drugs have been developed like paromomycin, miltefos-
ine (hexadecylphosphocholine), and liposomal amphotericin
B (LAB), providing additional treatment options to SSG
(sodium stibogluconate) and amphotericin B. Recent studies
in India show that a single intravenous infusion of liposomal
amphotericin B (sLAB) at 10mg/kg is highly effective in
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India [6] which is a great improvement over the 28-day
oral application of miltefosine or long term injections of
paromomycin. It has been suggested by the WHO Regional
Technical Advisory Group [7] and the WHO Advisory
Panel for Leishmaniasis Control [1] to use sLAB as the first
line drug for the VL elimination program in the Indian
subcontinent. In 2010 a WHO arrangement with Gilead
Sciences Inc., producing ambisome, provided a donation of
over 450,000 doses of ambisome over the next 5 years for
the treatment of VL patients in Bangladesh, Sudan (North
and South), and Ethiopia. Ambisome is currently the only
formulation of LAB registered by the United States Food and
Drug Administration (US-FDA) and in Bangladesh for the
treatment of VL. However, one important difficulty in the
application of ambisome is that it requires trained staff, the
equipment for IV infusion, testing of haemoglobin, and other
clinical parameters as well as special storage requirements
ensuring that the drug is not exposed to temperatures above
25∘C.
In Bangladesh, the treatment of almost all VL patients
is carried out through the public sector, treating patients
at subdistrict hospitals called Upazila Health Complexes
(UHCs). Bangladesh is the first country aiming at introducing
sLAB at the PrimaryHealth Care level for the treatment of VL
patients.
Currently icddr,b (International Centre for Diarrhoeal
Disease Research, Bangladesh) in collaboration with the
Directorate General of Health Services, Government of
Bangladesh, and TDR-WHO (Special Programme for
Research and Training in Tropical Disease at the World
Health Organization), Geneva has been conducting an
open trial with single dose ambisome treatment for VL
to determine the feasibility of implementing the drug for
the treatment of VL at the subdistrict hospital level in
Bangladesh. As a part of this study we assessed separately
whether the subdistrict hospitals have the necessary facilities
to implement ambisome, its acceptance by the hospital staff
and patients who have been treated in the above mentioned
trial, and compared prospects and limitations of sLAB
regimen with the miltefosine treatment which currently is
the first line drug for the treatment of VL in Bangladesh,
India, and Nepal.
2. Methods
2.1. Study Sites, Population, and Sampling. The study was
conducted in Mymensingh, the most VL endemic dis-
trict in Bangladesh; within Mymensingh the five most
VL affected subdistricts (upazilas) were included: Fulbaria,
Trishal, Bhaluka, Muktagacha, and Gaffogaon [8]. The study
included rural hospitals, UHCs in these five subdistricts,
VL program personnel at the UHC level and central level,
and VL patients treated with sLAB regimen or miltefosine.
All patients treated with single dose ambisome in the above
mentioned ongoing open trial were interviewed directly
and one month after treatment. VL patients treated with
miltefosine were identified through subdistrict hospital regis-
ters. Sample size considerations for the comparison between
sLAB and miltefosine treatment regimens are as follows:
after estimating the proportion of sLAB patients with side
effects (1.3% of vomiting within one month of treatment)
and of miltefosine patients (36% of vomiting as reported by
doctors) a sample size of 25 patients was calculated to reach
a significant difference in the most concerning side effect for
miltefosine (defining a power of 80% and a significance level
of 5%).
2.2. Methods. The study used the following mixed methods
of quantitative and qualitative data collection.
(a) Semistructured interviews, using a list of guiding
questions, were conducted with the hospital staff
(5 hospital directors, 5 medical officers for disease
control, 7 nurses, and 10 technicians). Interviews
with hospital head and medical staff were recorded
digitally for further clarification; answers by nurses
and technicianwere added to the checklist assessment
in written form. Doctors were asked about their
preference about the existing treatment regimen for
VL.
(b) A checklist for supplies required for the treatment
with ambisome was established, following the stan-
dard operation procedure (SOP) for ambisome treat-
ment used in the efficacy trial.
(c) Using the checklist direct observation of the facilities
in the UHC, where the eventual ambisome program
will be started, was performed.
(d) Interviews with VL patients treated with sLAB ormil-
tefosine were conducted using a structured question-
naire. Information was collected about their knowl-
edge, attitude, and practice for VL; their satisfaction
about the treatment received; and their preference for
sLAB or miltefosine.
Two focus group discussions (FGDs) with VL patients
treated with miltefosine were performed using a qualitative
method to gain a deeper insight into the general VL manage-
ment practise asmiltefosine patients represent the population
treated at the UHC under normal and no trial situation as for
sLAB patients.
2.3. Data Analysis. Data were entered using EPI Info (version
3.5.1). For data quality assurance, range and consistency
checks were performed. SPSS software (version 17.0) was used
for data analysis. Descriptive summary statistics including
mean, median, standard deviation, and range were explored.
Comparison between means or medians was performed by
using t-test or equivalent nonparametric test where applica-
ble.
Chi-square or Fisher test was used to compare pro-
portions of different groups as required. A two-tailed 𝑃
value ≤ 0.05 was considered significant. Open questions
were coded inductively. Qualitative data were analysed in
the following way: interviews and the FGDs were recorded
and transcribed into English as needed and content analysis
was performed. Themes of questionnaires were triangulated
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with the answers and grounded theory was used analysing
additionally emerging themes or newproblems described [9].
Transcripts were grouped and categorized into themes that
were treated in the questionnaires and new upcoming topics
were tabulated using Excel 2010.
3. Results
3.1. Opinions of Health Staff and Direct Observation of
Hospital Facilities. The five directors (Upazila Health and
Family Planning Officers (UH&FPO)) interviewed in the
rural hospitals (UHCs) of the five subdistricts (upazilas)
informed us that in each hospital there were 51 beds (at 3
of the 5UHCs) or that they were in the process of stocking
up from 31 to 51 beds (at 2 of the 5UHCs). The monthly bed
occupancy rate ranged from 70% to over 100% with a mean
of 88.3%. On average each month 23.3 VL patients (range
from 10 to 40) were treated at each UHC. In each UHC
the average number of doctors and nurses involved in VL
patients management was 1.8 (range, 1 to 2) and 2.4 (range,
2 to 4), respectively. Except for 1 UHC all directors reported
that two nurses at their UHCs had received training for the
preparation and administration of single dose ambisome that
had happened on average 1.5 years ago.
According to the directors the diagnosis and treatment
of VL patients were currently provided at no cost for VL
patients. However, according to the laboratory technicians,
the uninterrupted supply of rK39 rapid tests (the most
important laboratory tool for the diagnosis of VL) was
available in 3 of 5 hospitals. Haemoglobin testing facilities
were available at all hospitals.
The study team observed a total of 27 refrigerators in the
five hospitals; 12 were not functioning. Ice packs and ice boxes
were available in all hospitals. Refrigerators for maintaining
4∘C to 25∘C for drug storagewere not available in all hospitals.
Each UHC had a back-up generator for power during power
cuts. Directors reported average needs of 81.6 L of fuel per
month to bridge power cuts and an average amount of 57.5 L
of fuel to each UHC per month provided by the central
management.
The essential supplies needed for the implementation of
single dose ambisome in the five UHCs (see Table 1) were
not available in all of the hospitals. However the availability
of drugs for management of adverse events during treatment
with single dose ambisome was better (Table 2).
3.2. Experiences and Opinions of Medical Professionals regard-
ing the Feasibility of Single Dose Ambisome Treatment. Five
medical officers, seven nurses, and ten medical laboratory
technicians (five technicians of vaccine management and
five technicians of the pathology department) participated
in the study. All five doctors had treated VL patients on
average for 1.6 years; they all had experiences withmiltefosine
treatment, 4 out of 5 with antimonials (SSG), 1 out of 5 with
paromomycin, and 1 doctor with single dose ambisome. All 5
doctors had heard about the sLAB treatment regimen. Four of
them thought that sLAB application would be possible at the
rural hospital if essential logistics and supplies were available.
Table 1: Items needed for IV application of LAB and their availabil-
ity in 5 rural hospitals (UHCs) of Bangladesh.
Items for preparation of ambisome
treatment: availability
Item available at
UHCs
𝑛/𝑁
5% DA (500mL)
No continuous supply 3/5
Not available 2/5
Distilled water 10mL 0/5
Distilled water 5mL
No continuous supply 3/5
Not available 2/5
5% DA (500mL)
No continuous supply 3/5
Not available 2/5
Disposable infusion sets 0/5
Disposable syringe
10mL available 1/5
20mL available 0/5
Disposable syringe 5mL
Continuous supply 3/5
No continuous supply 2/5
Scissors available 4/5
Items for administration of ambisome
Gloves
Continuous 2/5
Not continuous 2/5
No 1/5
Cotton balls available 5/5
Chlorhexidine bottle (70%) 2/5
IV canulla 18 g
Continuous supply 3/5
No continuous supply 2/5
IV canulla 24 g 1/5
IV canulla 22 g 1/5
IV canulla 20 g 0/5
Micropore available 5/5
They felt the staff had sufficient time to handle the work of
preparing and applying single dose ambisome. Nurses in the
wards had similar views. The doctors mentioned that “VL
patient numbers are getting less” and “some nurses have already
been trained.” Two of the doctors had received training on
ambisome treatment. Three doctors mentioned difficulties
mainly because of the price of ambisome and availability
issues for the drug; one mentioned power disruption (“load
shedding”) as an issue and the need for storage facilities and
refrigerators. Others mentioned the need for trained staff. 4
of the 5 doctors thought that sLABwas the best option for VL
treatment.
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Table 2: Drugs needed to treat adverse events of sLAB treatment in
5 rural hospitals (UHCs).
Items for treatment of adverse events:
availability
Item available at
UHCs
𝑛/𝑁
Prophylactic treatment before
administration of sLAB
Paracetamol (tablets) available 5/5
Antihistaminic tablets available 5/5
First aid drugs
Nebulizer available 5/5
Adrenalin available 2/5
Chlorpheniramine available 5/5
Dexamethasone
Available 3/5
No continuous supply 2/5
First aid drugs are in one place 0/5
3.3. Views of the Deputy Program Manager of the National
Kala-Azar Control Program regarding the Feasibility of Single
Dose Ambisome Treatment in Rural Hospitals of Bangladesh.
The national director of Kala-azar control (Directorate Gen-
eral of Health Services, Government of Bangladesh) consid-
ers sLAB a highly effective treatment that required support
particularly during the implementation phase. He informed
us that the national programwas currently improving knowl-
edge and skills of human resources and building institutional
capacities. According to the director, in the past the WHO
funded training programs (96 doctors and 96 nurses). The
Director stated that a training program, for two doctors and
two nurses from 105UHCs of 105VL endemic sub districts
(upazilas), will be funded by the Government of Bangladesh.
The Director was well informed about the requirements for
implementing the single dose ambisome program in rural
hospitals of VL endemic areas. He mentioned the fuel for
generators, the need for more refrigerators, essential sup-
plies for ambisome administration, drugs for management
of adverse effects related to ambisome administration, and
training for hospital staff. He also mentioned that for the
supplies for administering single dose ambisome additional
funds might be needed. He was aware that for distribution of
ambisome, drugs, diagnostics, and other supplies will need
to be organised from the central level and mentioned that it
will be done using microplanning and checklists to monitor
and compare patients treated and supplies needed for each
month. The director hoped that in the next five years, during
the donation phase of ambisome, a substantial decline of
VL cases can be achieved and that after these five years the
national program can afford to continue sLAB treatment free
of cost for the patients due to less occurring VL cases.
3.4. Patients’ Experiences and Perceived Benefits of Miltefosine
versus sLAB Treatment. Disappearance of fever, the cardinal
symptom of VL, is the first clinical criterion for treatment
efficacy. The mean time for fever reduction was 2.5 (SD 0.9)
days and 17.6 (SD 11.3) days, 𝑃 < 0.001, for sLAB and
miltefosine, respectively (Table 3). During or after treatment
VL patients may experience nausea, vomiting, diarrhoea,
and abdominal pain. Patients who had been treated with
sLAB reported these symptoms less frequently compared to
miltefosine patients after one month (Table 3). Time to feel
better (recovery) and to start work again was significantly
less among the group treated with sLAB compared to those
treatedwithmiltefosine (Table 3). Using an average income of
a VL household member in Mymensingh of 0.3$, estimated
by Anoopa Sharma et al. in 2006 [10], the average income
loss due to recovery time was 2.2USD and 15.85USD, respec-
tively, for sLAB and miltefosine group. Finally, all patients
interviewed indicated in the interviews that they would
suggest sLAB treatment to other VL patients whereas the
recommendation for miltefosine was given by only 45.5% of
patients treated withmiltefosine. Likewise, in the focus group
discussions miltefosine treated patients were very critical
about their treatment and the majority would prefer a one
saline treatment staying one night in hospital.
4. Discussion
The introduction of a new drug into resource poor settings
requires special considerations and precautions. Examples
are the introduction of ACT for malaria treatment [11]
and TB drugs in the developing world [12]. Likewise, the
introduction of miltefosine, the first oral drug against VL,
required intensive testing and operational research to be
accepted as a first line drug in Bangladesh, India, and Nepal
[13].
Special requirements for introducing a new drug or
treatment scheme in a resource poor setting include the
following.
(i) The drug should be cost effective and high drug costs
would be prohibitive.
(ii) Logistics for drug distribution should be simple: dis-
tribution and storage should require little resources.
(iii) Drug management should be simple and the applica-
tion of the drug should require little skill.
(iv) Monitoring should be straightforward particularly
regarding the distribution and drug-related side
effects as well as compliance to the treatment.
Most of these requirements are better met by sLAB than
by miltefosine or the other VL drugs. There are, however,
along with the positive factors some drawbacks to sLAB
treatment, discussed below.
4.1. Preparing the Large Scale Introduction of sLAB as First Line
Treatment in Bangladesh. Enabling factors for the introduc-
tion of sLAB in Bangladesh were highlighted in this paper;
they include the following.
(i) Political commitment for the implementation of sin-
gle dose ambisome as first line VL treatment in
Bangladesh is high: SOPs are being developed, staff
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Table 3: Patients’ experiences and perceived benefits by the sLAB and miltefosine treatment regimen.
Indicator sLAB
𝑁 = 299
Miltefosine
𝑁 = 22
𝑃 value
Resolution of fever in days, mean (SD) 2.48 (0.86) 17.58 (11.34) <0.001
Nausea/vomiting after treatment % (𝑛) 1.3 (4) 86.4 (19) <0.001
Diarrhoea % (𝑛) 0.00 (0) 63.6 (14) <0.001
Abdominal pain % (𝑛) 0.7 (2) 27.3 (6) <0.001
Mean of time to recovery in days (SD) 2.39 (0.731) 17.36 (12.385) <0.001
Mean of time in days to start working
after treatment (SD) 2.72 (1.819) 52.82 (33.987) <0.001
Income loss due to recovery time 2.72 days × 0.30$
1/day
= 0.816$
52.82 days × 0.30$1/day
= 15.846$ <0.001
Income loss (working days lost when
receiving treatment)
2.39 days × 0.3$/d
= 0.72$
17.36 days × 0.3$/d
= 5.2$ <0.001
1Average daily income per person in a VL affected household in Bangladesh, calculated by Anoopa Sharma et al. 2006 [10].
training is taking place, and missing supplies will be
distributed from central level using microplanning.
(ii) WHO support: first training units for health staff have
been financed by TDR-WHO and have now been
handed over to the government. The drug donation
(see below) has been facilitated by WHO; the clinical
community trial has been supported by WHO.
(iii) Donation by the drug company (Gilead): over 445 000
vials will be donated over the coming 5 years; this has
eliminated one of the major obstacles, which were the
costs of the product.
(iv) Support by research institutions (particularly icddr,b):
the work since 2005 in relation to active case detec-
tion, case management, and drug efficacy has been an
important contribution to paving the way for better
first line treatments.
(v) Contributions of an NGO (MSF): through providing
a multiple dose of sLAB to 1439VL patients (15mg
in 3 doses over 5 days) over a period of 25 months,
the safety and efficacy of LAB could be underlined:
the initial cure rates were 99.6% and 2.7% relapses
(which occurred mainly 6 months after treatment),
[14]. Furthermore, the MSF experiences showed that
trained health workers were able to “independently
prepare and administer the appropriate dose” and
refer severe cases to the district hospital [14].
(vi) Feasibility according to our study: the general capac-
ities of the Upazila Health facilities regarding the
expected bed occupancy rate, expected case load
of VL patients per month, and patient : physician
and patient : nurse ratios were sufficient to perform
sLAB treatment at primary care level including the
hospitalization of VL patients for two days.
(vii) Acceptance of sLAB treatment (compared to miltefo-
sine treatment) by patients in our study: (a) sLAB
treatment was well tolerated showing only mild side
effects (short fever peak after infusion (80.94%) and
short duration) which were quickly forgotten by
the patients (documented by interviews one month
later). (b) sLAB treated patients showed very fast
recovery. (c) sLAB patients were satisfied and all
patients would recommend the treatment to others
and prefer a single infusion to tablets over 28 days. (A
certain level of bias has to be considered in the patient
interviews as the sLAB patients were interviewed in
a trial situation where many particular patient needs
could be met, which was not the case for miltefosine
treatment.) However, the overall positive response of
sLAB patients is in accordance with all other objective
and subjective assessments.
(viii) Other advantages of sLAB over miltefosine: (a) a single
dose treatment ensures 100% adherence rates and its
use is safe during pregnancy [15], which are clear
advantages over miltefosine where adherence issues
have been reported [16] and where pregnancy testing
and contraception during treatment are required but
rarely performed in reality [17]. (b) The fast recovery
(time to be able to work) of sLAB patients with 2.72
days compared to 52.82 days in miltefosine patients
reduces the income loss of the patients due to the
treatment by about 15$ which is a substantial amount
for poor people [18].
(ix) The preliminary assessment by doctors was very pos-
itive, describing sLAB as the best treatment option if
refrigerators would be provided.
However, according to our findings there are certain
requirements to be met when introducing sLAB treatment in
rural Bangladesh. These include the following.
(i) Cold chain issues are now less stringent for ambisome
as it can be stored below 25∘C but in tropical tem-
peratures refrigeration is still needed; refrigerators,
preferably ice lined refrigerators (ILRs), to bridge
power cuts should be provided to ensure the stability
of the drug.
(ii) Clinical monitoring tools like scales are needed and
their quality has to be assured.Themajority of supplies
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required for ambisome administration are not yet
available at all rural hospitals. Even when distributed
from central level for VL treatment it has to be
ensured that they are used for the purpose of sLAB
treatment only. Preparation and administration of
ambisome requires skilled human resources. Even
though side effects and previously observed serious
allergic reactions may be rare and even though MSF
reported that the LAB (triple dose) treatment was
managed properly by primary health care workers
in rural Bangladesh, health staff should be able to
manage potential adverse reactions such as drop of
haemoglobin, allergic reactions, and drop in blood
pressure.
5. Conclusion
Comparing favouring and limiting factors, the enabling fac-
tors clearly outweigh the limiting factors for sLAB treatment
in Bangladesh. As the efficacy trial under field conditions has
shown favourable results [19] the sLAB treatment appears
to be the most promising option for VL treatment in
Bangladesh.
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